A novel myeloablative regimen in cord blood transplantation was investigated for patients with active diseases
The regimen provided reliable engraftment and durable remission with acceptable nonrelapse mortality
Overall survival and progression-free survival were both estimated as 54.9% at 2 years after transplantation